KRAS and neoplasm: Other mechanisms of PD-L1 upregulation are overexpression of Myc along with mutated KRAS; activating mutations of EGFR, KRAS or JAK2; and CMTM4 and CMTM6 posttranslational regulation in tumor cells and DCs, in addition to other posttranscriptional modifications [96].